Collegium Pharmaceutical Company Leadership
| COLL Stock | USD 30.18 0.38 1.24% |
Collegium Pharmaceutical's insiders are aggressively selling. The analysis of insiders' sentiment of trading Collegium Pharmaceutical stock suggests that most insiders are panicking at this time. Collegium Pharmaceutical employs about 357 people. The company is managed by 17 executives with a total tenure of roughly 21 years, averaging almost 1.0 years of service per executive, having 21.0 employees per reported executive.
| Scott Dreyer President Executive Vice President Chief Commercial Officer |
| Joseph Ciaffoni President COO, Executive Vice President |
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-03-14 | Scott Dreyer | Disposed 2255 @ 30 | View | ||
| 2025-03-11 | Colleen Tupper | Disposed 10445 @ 30.01 | View | ||
| 2025-03-06 | Shirley R Kuhlmann | Disposed 26067 @ 28.5 | View | ||
| 2025-03-04 | Shirley R Kuhlmann | Disposed 40000 @ 28.08 | View | ||
| 2025-01-10 | Shirley R Kuhlmann | Disposed 27500 @ 33.04 | View | ||
| 2024-09-13 | Thomas B Smith | Disposed 9593 @ 36.62 | View | ||
| 2024-09-05 | Shirley R Kuhlmann | Disposed 19248 @ 38.3 | View | ||
| 2024-05-28 | Colleen Tupper | Disposed 19710 @ 34.21 | View | ||
| 2024-05-24 | Scott Dreyer | Disposed 56807 @ 33.98 | View | ||
| 2024-05-14 | Garen G Bohlin | Disposed 28985 @ 32.3 | View |
Monitoring Collegium Pharmaceutical's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Collegium |
Collegium Pharmaceutical's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Collegium Pharmaceutical's future performance. Based on our forecasts, it is anticipated that Collegium will maintain a workforce of about 360 employees by April 2025.Collegium Pharmaceutical Management Team Effectiveness
The company has return on total asset (ROA) of 0.0889 % which means that it generated a profit of $0.0889 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3262 %, meaning that it created $0.3262 on every $100 dollars invested by stockholders. Collegium Pharmaceutical's management efficiency ratios could be used to measure how well Collegium Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 0.12 this year. Return On Capital Employed is expected to rise to 0.15 this year. At this time, Collegium Pharmaceutical's Return On Tangible Assets are quite stable compared to the past year. Intangibles To Total Assets is expected to rise to 0.67 this year, although the value of Total Current Assets will most likely fall to about 268.4 M.The value of Common Stock Shares Outstanding is expected to slide to about 31.3 M. The value of Net Loss is expected to slide to about (30.2 M)
Collegium Pharmaceutical Workforce Comparison
Collegium Pharmaceutical is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 42,271. Collegium Pharmaceutical maintains roughly 357 in number of employees contributing less than 1% to equities under Health Care industry.
Collegium Pharmaceutical Profit Margins
The company has Profit Margin (PM) of 0.11 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.24 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.24.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.65 | 0.5976 |
|
|
Collegium Pharmaceutical Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Collegium Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Collegium Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Collegium Pharmaceutical insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 0.5417 | 13 | 24 | 412,717 | 335,535 |
| 2024-06-01 | 1.2222 | 11 | 9 | 165,529 | 285,696 |
| 2024-03-01 | 0.7143 | 10 | 14 | 549,546 | 254,388 |
| 2023-12-01 | 0.5 | 5 | 10 | 98,725 | 197,450 |
| 2023-06-01 | 1.1429 | 8 | 7 | 78,336 | 143,071 |
| 2023-03-01 | 0.625 | 10 | 16 | 495,837 | 267,192 |
| 2022-12-01 | 0.6071 | 17 | 28 | 377,362 | 565,569 |
| 2022-06-01 | 9.0 | 9 | 1 | 130,125 | 0.00 |
| 2022-03-01 | 0.6316 | 12 | 19 | 476,680 | 178,429 |
| 2021-06-01 | 0.9 | 9 | 10 | 127,792 | 62,719 |
| 2021-03-01 | 1.1786 | 33 | 28 | 1,864,768 | 278,224 |
| 2020-12-01 | 0.25 | 1 | 4 | 16,000 | 33,699 |
| 2020-09-01 | 0.2222 | 2 | 9 | 15,082 | 21,638 |
| 2020-06-01 | 1.125 | 18 | 16 | 169,956 | 215,276 |
| 2020-03-01 | 0.875 | 14 | 16 | 671,329 | 599,918 |
| 2019-12-01 | 0.4444 | 4 | 9 | 106,869 | 1,359,236 |
| 2019-09-01 | 0.1429 | 2 | 14 | 20,650 | 83,351 |
| 2019-06-01 | 1.8 | 18 | 10 | 240,468 | 91,384 |
| 2019-03-01 | 0.8333 | 10 | 12 | 397,600 | 92,995 |
| 2018-12-01 | 0.1429 | 1 | 7 | 5,859 | 479,683 |
| 2018-09-01 | 0.5714 | 4 | 7 | 83,283 | 79,253 |
| 2018-06-01 | 1.1875 | 19 | 16 | 180,276 | 371,622 |
| 2018-03-01 | 0.8571 | 18 | 21 | 481,967 | 686,146 |
| 2017-12-01 | 0.375 | 6 | 16 | 17,557 | 4,460,223 |
| 2017-09-01 | 1.0 | 4 | 4 | 27,122 | 1,136 |
| 2017-06-01 | 9.0 | 9 | 1 | 472,669 | 0.00 |
| 2017-03-01 | 0.9286 | 13 | 14 | 311,082 | 128,982 |
| 2016-06-01 | 4.6667 | 14 | 3 | 85,804 | 13,604 |
| 2016-03-01 | 7.0 | 7 | 1 | 210,916 | 0.00 |
| 2015-06-01 | 0.7292 | 35 | 48 | 17,746,568 | 72,114,740 |
| 2006-03-01 | 3.0 | 6 | 2 | 88,370 | 0.00 |
| 2005-06-01 | 0.5 | 1 | 2 | 25,000 | 3,968 |
Collegium Pharmaceutical Notable Stakeholders
A Collegium Pharmaceutical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Collegium Pharmaceutical often face trade-offs trying to please all of them. Collegium Pharmaceutical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Collegium Pharmaceutical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Vikram Karnani | President CEO | Profile | |
| RPh Pharm | Chairman, CoFounder | Profile | |
| Scott Dreyer | Executive Vice President Chief Commercial Officer | Profile | |
| Joseph Ciaffoni | COO, Executive Vice President | Profile | |
| Shirley Kuhlmann | Executive Vice President General Counsel, Secretary | Profile | |
| Colleen Tupper | Executive CFO | Profile | |
| Shirley JD | General VP | Profile | |
| Bart Dunn | Executive Development | Profile | |
| Scott Sudduth | Head Operations | Profile | |
| Christopher MD | Vice Relations | Profile | |
| Marlo Manning | Head HR | Profile | |
| David Dieter | Executive Counsel | Profile | |
| Alex Dasalla | Head Relations | Profile | |
| Richard MD | Ex Officer | Profile | |
| Jane Gonnerman | Executive Development | Profile | |
| MD FAAFP | Executive Officer | Profile | |
| Dean Patras | Chief Officer | Profile |
About Collegium Pharmaceutical Management Performance
The success or failure of an entity such as Collegium Pharmaceutical often depends on how effective the management is. Collegium Pharmaceutical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Collegium management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Collegium management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.11 | 0.12 | |
| Return On Capital Employed | 0.15 | 0.15 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.30 | 0.32 |
Collegium Pharmaceutical Workforce Analysis
Traditionally, organizations such as Collegium Pharmaceutical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Collegium Pharmaceutical within its industry.Collegium Pharmaceutical Manpower Efficiency
Return on Collegium Pharmaceutical Manpower
| Revenue Per Employee | 1.8M | |
| Revenue Per Executive | 37.1M | |
| Net Income Per Employee | 193.8K | |
| Net Income Per Executive | 4.1M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.62) | Earnings Share 1.86 | Revenue Per Share | Quarterly Revenue Growth 0.215 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.